APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC

Slideset - Pertuzumab addition significantly reduced risk of invasive DFS at 3 years.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research